- Who we areWho we are
We are a biotechnology company committed to helping address serious infectious diseases globally through the discovery and development of innovative vaccines to patients around the world.
Build your future with usJoin other passionately curious people who are bringing innovative vaccines to the world
- What we doWhat we do
Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.
COVID-19 UPDATESNovavax has demonstrated its ability to quickly develop viable vaccine candidates for emerging infectious diseases such as COVID-19.
- Blog
Novavax Grows Presence at World Vaccine Congress 2023 and 33rd European Congress of Clinical Microbiology & Infectious Diseases
GAITHERSBURG, Md., April 4, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, will present data on its COVID-19 prototype vaccine and its COVID-Influenza Combination vaccine candidate (CIC) at both the World Vaccine Congress 2023 (WVC) in Washington, DC, April 3 to 6, 2023, and the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen, Denmark, April 15 to 18, 2023.
At WVC, Novavax will present data on its COVID-19 prototype vaccine as a booster and its CIC. Novavax will also host an Insights and Tools to Counter Vaccine Hesitancy roundtable on April 4, and participate in a panel discussion on The Future of Safety for New Vaccines on April 5. In addition, Novavax has been named a finalist for the 2023 World Vaccine Congress Vaccine Industry Excellence Awards (ViE) in the Best New Vaccine Technology/Platform Award and Best COVID Vaccine Award categories. Winners will be announced in-person at the ViE Awards ceremony during WVC on April 4.
At ECCMID, the Company will present the CIC data and four poster presentations on its COVID-19 prototype vaccine.
Novavax presentations during WVC:
Author | Presentation title | Details |
Dunkle, L | Novavax COVID-19 Vaccine: | Oral Presentation April 5, 2023 10:10am (EDT) |
Shinde, V | Update on Novavax Influenza | Oral Presentation April 5, 2023 3:25pm (EDT) |
Fix, J | Safety surveillance for COVID-19 | Oral Presentation April 5, 2023 12:10pm (EDT) |
Novavax presentations during ECCMID:
Author | Presentation title | Details |
Shinde, V | Immunogenicity of a novel | Oral Presentation Abstract #02042 April 16, 2023 8:30am (CEST) |
Toback, S | Interim analysis of an observer- | Poster Presentation Poster #P2698 April 17, 2023 12:00pm (CEST) |
Marchese, A | Reported pregnancy outcomes | Poster Presentation Poster #P2521 April 17, 2023 12:00pm (CEST) |
Marchese, A | Healthcare provider perceptions of | Poster Presentation Poster #P2755 April 17, 2023 12:00pm (CEST) |
Bennett, C | LATE-BREAKER: Immunogenicity | Poster Presentation Poster #LB039 April 18, 2023 12:00pm (CEST) |
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world's most urgent health challenges, Novavax is currently evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined. Please visit novavax.com and LinkedIn for more information.
The World Vaccine Congress
The World Vaccine Congress is a series of conferences and exhibitions that have grown over 23 years to become the largest vaccine meetings of their kind across the globe. The event format allows for whole-sector topics with hundreds of speakers and covers the complete vaccine value chain, enabling thousands of attendees from science, government, and manufacturers to come together to create ground-breaking progress. More information can be found at https://www.terrapinn.com/conference/world-vaccine-congress-washington/index.stm.
CONTACTS
Investors
Erika Schultz
240-268-2022
[email protected]
Media
Ali Chartan
240-720-7804
[email protected]
SOURCE Novavax, Inc.
